Table 3.
Multivariate Cox proportional regression analysis for the association with recurrence-free survival and overall survival of (A) phospho-FAK staining score in NSCLC (n = 95) and (B) the ratio between phospho-FAK and FAK staining scores in SCLC patients (n = 105).
| A | ||||
|---|---|---|---|---|
| Variable | Recurrence-Free Survival | Overall Survival | ||
| HR (95% CI) | p-Value | HR (95% CI) | p-Value | |
| Stage (ref: I) | ||||
| II | 1.06 (0.35–3.20) | 0.92 | 0.63 (0.19–2.04) | 0.44 |
| III | 1.92 (0.72–5.16) | 0.19 | 2.76 (1.11–6.83) | 0.03 |
| IV | 5.64 (1.79–17.7) | <0.01 | 3.21 (1.06–9.66) | 0.04 |
| Age at diagnostic (ref: <75 y/o) | ||||
| >75 y/o | 1.19 (0.49–3.07) | 0.72 | 0.75 (0.28–2.03) | 0.57 |
| Smoking history (ref: ex and never) | ||||
| Current | 0.82 (0.35–1.89) | 0.64 | 0.88 (0.39–1.96) | 0.75 |
| Histology (ref: ADC) | ||||
| SCC | 0.66 (0.26–1.69) | 0.39 | 1.59 (0.70–3.62) | 0.27 |
| Phospho-FAK staining score | 0.99 (0.98–1.00) | 0.15 | 0.99 (0.98–1.01) | 0.30 |
| B | ||||
| Variable | Recurrence-Free Survival | Overall Survival | ||
| HR (95% CI) | p -Value | HR (95% CI) | p -Value | |
| Stage (ref: LD) | ||||
| ED | 3.75 (2.08–6.78) | <0.01 | 3.47 (1.91–6.32) | <0.01 |
| Age at diagnostic (ref: <75 y/0) | ||||
| >75 y/o | 1.56 (0.93–2.63) | 0.09 | 1.42 (0.88–2.29) | 0.15 |
| Smoking history (ref: ex and never) | ||||
| Current | 1.23 (0.78–1.93) | 0.37 | 1.11 (0.73–1.70) | 0.62 |
| 100 × ratio phospho-FAK/FAK staining scores | 0.95 (0.89–1.02) | 0.14 | 1.00 (0.97–1.03) | 0.87 |
Abbreviations: ADC, adenocarcinoma; CI, confidence interval; ED, extensive-stage disease; LD, limited-stage disease; FAK, focal adhesion kinase; HR, hazard ratio; SCC, squamous cell carcinoma; y/0: Years old.